Fakultni Nemocnice Hradec Kralove

Research site

Czechia Sokolska 581, Novy Hradec Kralove, 500 03 Hradec Kralove, Czechia

73 trials recruiting
Hereditary angioedema · Colorectal cancer metastatic · Plasma cell myeloma
Adults and children

About Specializations

Fakultni Nemocnice Hradec Kralove in Hradec Kralove, Czechia specialises in clinical trials of conditions such as Hereditary angioedema, Colorectal cancer metastatic, Plasma cell myeloma, Plasma cell myeloma refractory, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Sokolska 581, Novy Hradec Kralove500 03 Hradec KraloveCzechia

Open in maps ↗

Recruiting now: 73 trials
Conditions studied: 94

More sites in Hradec Kralove Czechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

101 clinical trials

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Lunsekimig
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting

Investigational

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational

Czechia

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Primary progressive multiple sclerosis

Recruiting

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Czechia

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Navenibart
Sponsor:Astria Therapeutics Inc.

Contact Research Centre

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Visugromab
Sponsor:CatalYm GmbH

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational

Czechia

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:VHB937
Sponsor:Novartis Pharma AG

Contact Research Centre

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Clazakizumab
Sponsor:CSL Behring LLC

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites